GlassScriptPhysician profile
Douglas S Miller
NPI 1881622405
$9,021.12
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $758 · 2021: $1,490 · 2022: $2,145 · 2023: $1,878 · 2024: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.81 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,834.99 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,197.94 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $1,106.38 | 2019-2024 | Blu-U, Odomzo, Ilumya |
| Genzyme Corporation | $705.18 | 2019-2024 | |
| Amgen INC. | $523.44 | 2020-2023 | Otezla |
| Lilly USA, LLC | $425.98 | 2019-2024 | Taltz, Olumiant |
| Leo Pharma INC. | $403.10 | 2019-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $369.55 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $340.65 | 2019-2023 | Aklief, Epsolay, Oracea |
| E.R. Squibb & Sons, L.L.C. | $284.84 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $261.64 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $215.62 | 2019-2024 | |
| Prugen, INC. Pharmaceuticals | $183.17 | 2019 | |
| Pfizer INC. | $174.20 | 2021-2023 | |
| Arcutis Biotherapeutics, INC. | $163.60 | 2023-2024 | Zoryve |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $153.70 | 2019-2024 | Bimzelx |
| Celgene Corporation | $143.81 | 2019 | |
| Dermavant Sciences, INC. | $103.74 | 2023-2024 | Vtama |
| Incyte Corporation | $69.74 | 2022-2024 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.52 | 2020-2023 | Arazlo, Jublia |
| Journey Medical Corporation | $43.78 | 2022-2023 | |
| Allergan, INC. | $43.14 | 2019-2021 | |
| Genentech USA, INC. | $38.86 | 2021-2024 | Erivedge |
| Almirall LLC | $34.35 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $23.19 | 2019 | |
| Dermira, INC. | $22.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2023 | Spevigo |
| Aclaris Therapeutics, INC. | $18.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.99 | 2019 | |
| Sandoz INC. | $15.00 | 2020 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.